



## Minutes of the Physician Assistant Policy Committee

January 14, 2019

**MEMBERS PRESENT:** Curtis Gingrich, M.D., Chair; Scott Cackler, PA-C; Jessica Thurman, PA-C; Corey Coffey, Pharm.D.; Megan Marchal, Pharm.D., Pharmacy Board member; Kindra Engle, D.O.; and Richard Edgin, M.D.. Medical Board member

**ALSO PRESENT:** Robert Giacalone, J.D.; Sallie Debolt, Senior Counsel; Vanessa Phillips, Pharm.D.

The meeting was called together by Dr. Gingrich at approximately 8:35 am.

All persons attending introduced themselves.

Minutes of December 10, 2018 meeting: Mr. Cackler moved to approve as drafted. Upon Dr. Engle's second, the motion passed unanimously.

Placement of medication-assisted treatment drugs on the formulary. At the December 2018 meeting the committee voted to place all of the drugs as "may prescribe" but did not determine how to physically place them on the formulary. Mr. Cackler moved, and Mr. Coffey seconded, that a separate category be created to list all of the MAT drugs as were approved in December 2018.

Dr. Engle entered the meeting at this time.

### New Drug Approvals: October 2018 through November 2018

**Seysara:** Ms. Thurman moved, and Mr. Cackler seconded the motion to list the drug as "may prescribe" under Systemic anti-infective agents > Antibacterials > Tetracyclines. The motion was approved unanimously.

**Nuzyra:** Ms. Thurman moved to list as "may prescribe" for both routes of administration under Systemic anti-infective agents > Antibacterials > Tetracyclines. Mr. Coffey seconded the motion, which passed unanimously.

**Tegsedi:** Dr. Engle moved to list the drug as "may not prescribe" under Neurologic Agents > Misc Agents > Antisense oligonucleotides because of the risks involved and will likely be a specialty-based practice. Dr. Edgin seconded the motion, which passed unanimously.

**Revocoi:** Ms. Marchal moved to list the drug as "may not prescribe" under Hormone and Synthetic Substitutes > Misc. Hormone and Synthetic Substitutes > creating a new listing for Recombinant Adenosine Deaminases. Upon Mr. Coffey's second the motion passed unanimously.

**Talzenna:** Dr. Edgin moved, and Mr. Cackler seconded, a motion that the drug be listed under Antineoplastics > Protein Synthesis Inhibitors as "may not prescribe." The motion passed unanimously.

---

**Xofluza:** Dr. Engle moved to place under Systemic anti-infective agents > Antivirals under a new category of PA endonuclease inhibitors as “may prescribe.” Mr. Cackler seconded the motion, which passed unanimously.

**Hyrimoz:** Mr. Cackler moved to list under Misc. Therapeutic Agents > Disease-modifying anti-rheumatic agents as “physician initiated/consultation.” Mr. Coffey seconded the motion, which passed unanimously.

**Lorbrena:** Mr. Cackler moved to list the drug under Antineoplastics > Kinase Inhibitors as “may not prescribe.” Upon Dr. Edgin’s second, the motion passed unanimously.

**Udenyca:** Dr. Edgin moved to place the drug under Blood Formation, Coagulation, and Thrombosis > Hematopoietic Agents > Colony Stimulating Factors and “physician initiated per protocol.” Ms. Thurman seconded the motion, which passed unanimously.

**Yupelri:** Dr. Engle moved to place the drug under Respiratory Tract Agents > Bronchodilators as “may prescribe.” Upon Ms. Thurman’s second, the motion passed unanimously.

**Aemcolo:** Dr. Engle moved to list the drug under Systemic anti-infective agents > Antibacterials > Rifamycins as “physician initiated/consultation.” Mr. Cackler seconded the motion, which passed unanimously.

**Gamifant:** Dr. Engle moved, and Ms. Thurman seconded, a motion to place the drug under Hormone and Synthetic Substitutes > Misc. Hormone and Synthetic Substitutes > create new listing for Monoclonal antibodies as “may not prescribe.” The motion carried unanimously.

**Daurismo:** Mr. Coffey moved to list the drug as “may not prescribe” under Antineoplastics > Hedgehog Pathway Inhibitor. Ms. Thurman seconded the motion. The motion passed unanimously.

**Vitrakvi:** Dr. Edgin moved to list the drug under Antineoplastics > Kinase Inhibitors as “may not prescribe.” Upon Ms. Thurman’s second the motion passed unanimously.

**Firdapse:** It was discussed that although the drug is a potassium channel blocker it is not indicated for multiple sclerosis. Dr. Edgin moved that the drug be listed under Neurologic Agents > Misc. Agents > creating a new listing for Cholinergic agonists as “neurologist initiated.” Dr. Engle seconded the motion, which passed unanimously.

**Xospata:** Mr. Cackler moved, and Dr. Edgin seconded, that the drug be listed as “may not prescribe” under Antineoplastics > Kinase Inhibitors. The motion passed unanimously.

**Truxima:** Dr. Edgin moved, and Mr. Coffey seconded, that the drug be listed as “may not prescribe” under Antineoplastics > Monoclonal antibodies. The motion passed unanimously.

Ms. Phillipps left the meeting at this time.

**Summary of Senate Bill 259:** Ms. Debolt gave a summary of SB 259. The changes include that there will no longer be a formulary, PAPC meetings can be conducted via video conference

or phone conference, PAPC will meet as needed instead of a minimum of four times per year, and there will only be one pharmacist on the committee. Ms. Debolt stated that at the next PAPC meeting she will present any changes to the physician assistant rules that are needed to conform to the new provisions of the Revised Code.

Upon the motion of Mr. Cackler, seconded by Ms. Thurman, the committee voted unanimously not to review drugs at the February meeting.

Ms. Debolt reported that letters will go out soon to notify the Ohio State Medical Association and the Ohio Association of Physician Assistants of expiring terms that will require the associations to nominate persons for appointment.

There was general discussion of possible meeting days in the future.

Dr. Gingrich adjourned the meeting upon the motion of Ms. Thurman.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on June 11, 2018.

---

Curtis Gingrich, Chair, PAPC



